Tachyon Therapeutics is focused on developing innovative cancer therapies, particularly through the exploration of novel drug targets. Their lead candidate, TACH101, is a first-in-class small-molecule inhibitor of the KDM4 family of histone demethylases, which play a critical role in regulating gene expression and tumorigenesis. By inhibiting KDM4, TACH101 aims to block the proliferation of various cancer cell lines and reduce tumor growth significantly, as demonstrated in preclinical studies. This compound is currently undergoing a Phase 1 clinical trial to evaluate its safety and efficacy in patients with advanced cancers, highlighting Tachyon's commitment to advancing therapeutics that target the underlying mechanisms of cancer.

In addition to TACH101, Tachyon is also developing TACH204, a monoclonal antibody targeting LEFTY1, which is believed to contribute to the growth of malignant epithelial stem cells and breast cancer development. This partnership with AbCellera Biologics Inc. underscores Tachyon's strategy of leveraging external expertise to enhance their drug development pipeline. The company's approach combines a strong scientific foundation in molecular cancer biology with rigorous clinical development processes, aiming to deliver breakthrough therapies that address significant unmet medical needs in oncology.

United States

Tachyon is accelerating innovative science to develop first-in-class therapeutics against significant new drug targets in cancer biology. Tachyon operates with a dedicated internal core development team and a world-class external network of expertise to achieve one goal - advance our programs with speed, innovation, quality and scientific integrity.

Tachyon Therapeutics

Company Details